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Summary
Objectives Statins are a well-known primary and secondary
prevention drug forcardiovascular disease and NICE guidelines have been
issued to identify key indicators for their use. An audit looking into statin
prescribing for medical inpatients was carried out in two geographically
distinct London hospitals.
Design A prospective inpatient audit of medical prescription charts was
performed. Blood results were reviewed for the inpatients during their
admission to identify any contraindications for statin usage
(rhabdomyolysis). The medical notes were also reviewed for patient
refusal of statin therapy.
Setting The study was carried out at two distinct hospitals in London.
Whipps Cross University Hospital (WCUH) and Chelsea & Westminster
Hospital (CWH) are located in East London and West London, respectively.
Acute medical, surgical, obstetrics and gynaecology, paediatric and
palliative wards were excluded.
Participants A total of 309 inpatient medical notes and prescription
chart data were collected from WCUH (n= 211) and CWH (n= 98).
Main outcome measures High percentage of hospitalized patients
are not prescribed statins despite clear clinical indications for their use.
Regardless of geographical and socioeconomic factors between hospitals,
statin prescribing remains suboptimal.
Results The patient demographics in both hospitals were very similar;
the mean age at WCUH was 78±15 1SD while at CWH the mean age was
74±15 1SD. The results showed that approximately one-third of patients
(30% at WCUH and 33% at CWH) had at least one indication for statin
therapy according to NICE guidelines and yet they were not prescribed
DECLARATIONS
Competing interests
None declared
Funding
None
Ethical approval
Obtained in
accordance with the
ethics/audit
committee of
Whipps Cross
University Hospital,
and Chelsea and
Westminster
Hospital;
conﬁdentiality
regarding all patient
notes was
maintained
throughout and there
w a sn ob r e a c ho f
conﬁdentiality during
data handling and
processing; all data
were encrypted
Guarantor
RS
J R Soc Med Sh Rep 2011;2:63. DOI 10.1258/shorts.2011.011027
RESEARCH
1a statin. Ten percent of patients at WCUH and 13% of patients at CWH had
ischaemic heart disease (IHD) and yet were not prescribed statins.
Conclusion Statin prescription is often overlooked in secondary care
with patients being discharged without the appropriate assessment (NICE
guidelines), which subsequently means repeat prescriptions are not
provided by the GP. This study is the ﬁrst to show that this problem is not
due to resources or geography, but is inherent within the NHS system.
Consequently, a revised prescription chart checking system has been
suggested for pharmacists and junior doctors.
Introduction
Coronary heart disease (CHD) is the most
common cause of death in the UK, with around
94,000 deaths annually.
1 The underlying pathol-
ogyof CHD isthe progression of atherosclerosis,
2,3
for which one of the main risk factors is hyper-
cholestrolaemia.
4,5 Statins are used to lower LDL
levels, through the inhibition of the rate-
determining step of cholesterol synthesis in the
liver.
6 Numerous trials have proven that second-
ary prevention with statins considerably improves
mortality and morbidity.
7 In addition, primary
prevention strategies for cardiovascular disease
(CVD) lead to signiﬁcant risk reductions; 12% in
all cause mortality, 30% in major coronary
events, and 19% in major cerebrovascular events.
8
The social and economic burden of CVD is an
ever more serious problem with the increasing
prevalence of adverse lifestyle practices and the
ageing UK population. The National Institute for
HealthandClinicalExcellence(NICE)hasidentiﬁed
this problem and issued clinical guidelines for
the use of statins in primary and secondary preven-
tion.AdultswithahistoryofCVDareautomatically
recommended for statin prescription and adults
with a 10-year risk of developing CVD equal to or
greater than 20% should start statin therapy as
primary prevention.
The effective adherence to clinical guidelines is
crucial in improving patient outcomes as it deﬁnes
a standard practice across the nation using the
latest evidence.
9 This benchmark standardization
provides cost efﬁciency and efﬁcacy especially in
preventative medicine, where a rigorous systema-
tic approach to drug prescription is necessary for
clinical outcomes. In addition, if hospitals initiate
changes to a patient’s primary management, then
this is often continued into primary care.
10
The report that governs the NICE guidelines
has identiﬁed a large number of signiﬁcant risk
factors for CHD for which statins have been
found to reduce the risk of these events (Table 1).
Since the guidelines have been announced,
there has been no published data highlighting
the prescribing patterns of statins in the UK. This
audit, using current NICE guidelines, is a cross-
sectional prospective study that identiﬁed the
prescribing levels of statins in two geographically
distinct regions within London. A city-wide study
was necessary to provide an accurate sample to be
analysed, so that valid conclusions could be
obtained on statin prescription.
The regions considered include a relatively
deprivedareacoveredbyWCUHandamoreafﬂu-
ent area covered by CWH. Previous studies have
highlighted the relationship between socioeco-
nomic status and prescribing habits; people living
in more afﬂuent areas have higher rates of statin
prescriptioncomparedtothoseindeprivedareas.
11
Table 1
Indications for statin therapyas recommended by
NICE. Clinical evidence of any of these conditions
should prompt statin therapy
7,14
Ischaemic heart disease
Angina
Myocardial infarction
Chronic heart disease
Cerebrovascular accidents
Transient ischaemic attack
Hypercholesterolaemia
Peripheral arterial disease
Combination of risk factors
Hypertension
Type 2 diabetes mellitus
Age > 70 years
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Honer KadrIt was envisaged that the advent of NICE
guidelines would enforce correct statin therapy,
especially in high-risk patients such as those
with a history of CVD. This study aims to assess
the level of statin prescribing in accordance to
NICE guidelines.
Methods
All inpatient medical notes and prescription chart
data were collected from two hospitals of distinct
geographical location: WCUH and CWH. Blood
results were reviewed during inpatient stay to
exclude any contraindications for statin usage,
such as rhabdomyolysis. The medical notes were
also reviewed for patient refusal of statin therapy.
Inclusion and exclusion criteria
Patients admitted under the medical specialties,
such as cardiology, gastroenterology, renal, respir-
atory, stroke, infectious disease and elderly care
medicine were included in this audit. Patients
from acute medical wards (Medical Assessment
Unit, Accident and Emergency) were excluded
due to the high rate of patient turnover while
other wards (Obstetrics and Gynaecology, Paedia-
trics, Surgery, Palliative Care) were excluded as we
felt the patient groups were not appropriate
targets for statin usage.
Twelve CVD risk factors speciﬁed in the NICE
guidelines were considered in this study as an
indication for statin prescription. These were:
hypercholesteraemia, hypertension, ischaemic
heart disease, acute coronary syndrome (ACS),
angina, myocardial infarction (MI), diabetes melli-
tus (DM), chronic cardiac failure (CCF), peripheral
vascular disease, coronary artery bypass graft
(CABG), cerebral vascular accident, transient
ischaemic attack (TIA).
7
Data were collected by a different team located
at each centre, and then both sets of data were
inserted into an electronic database by another
team. The database was veriﬁed by senior cardiol-
ogiststoensurethattheindicationsforstatinusage
were indeed present (as advised by the NICE
guidelines). After the veriﬁcation process was
complete, the data-set was redistributed to the
data anlaysis team. The teams consisted of
doctors,administrationstaffandmedicalstudents.
Results
A total of 309 patients were identiﬁed and col-
lected from both centres: 211 from WCUH (215
identiﬁed of which four were excluded due to
Figure 1
Graph showing the most frequent indications found in at-risk patients who were not prescribed statins.
IHD =ischaemic heart disease; PVD =peripheral vascular disease; CVA =cardiovascular event; Chol =
hypercholesteraemia; HTN =hypertension; DM =diabetes mellitus; RF (risk factor) combination=
hypertension, diabetes mellitus and age older than 70 years
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3inability to validate data) and 98 from CWH (98
identiﬁed, 0 excluded).
Demographics
At WCUH the mean age of patients was 78±15
1SD, with 48% men and 52% women. CWH had
a mean patient age of 74±15 1SD, with 50% men
and 50% women. The total data-set gives a mean
patient age of 77±15 1SD, with 49% men and
51% women.
Statin prescription
At WCUH, among the 211 inpatients, 30% of
patients had CVD risk factors but were not
prescribed statins in accordance with NICE guide-
lines. Similarly, at CWH, among the 98 inpatients,
33% of patients had CVD risk factors but were not
prescribed statins to reduce their riskof cardiovas-
cular events.
From the group of at-risk patients for whom
statin is indicated but not prescribed, 17% of
WCUH patients and 19% of CWH patients suf-
fered from ischaemic heart disease. Cerebral vas-
cular accident is the most neglected indication,
10% of patients from CWH and 5% of patients
from WCUH have a past history of cerebral vascu-
lar accident. Figure 1 illustrates in this group of
neglected at-risk patients, the most common
CVD risk factors are: ischaemic heart disease
(18%), cerebral vascular accident (8%), hypercho-
lesterolaemia (1%) and peripheral vascular
disease (1%). Additionally, 40% of these patients
are over the age of 70 and suffer from a combi-
nation of hypertension and diabetes.
Conversely, there were patients for whom
statins were not indicated, but were prescribed
the drug; they comprised 6% of the statin-taking
population at WCUH and 5% of statin-taking
population at CWH (Figure 2).
Discussion
The aim of this cross-sectional study was to ident-
ify whether NICE guidelines on statin prescription
were being effectively implemented across two
geographically distinct hospitals in London.
The results indicate that there are a large
number of patients who should be on a statin,
according to NICE guidelines, but are not. It
may be that this discrepancy results from clinician
unfamiliarity with the actual guidelines which
would also explain why some patients are on
statins, despite statins not being clinically indi-
cated. However, it is notable that the omissions
in statin prescription decrease with an increase
in the number of CVD risk factors the patient
has, i.e. a patient with a single CVD risk factor is
less likely to be prescribed the statin which he
needs than a patient with two or more CVD risk
factors. Having said this, 29% of WCUH patients
and 37% of CWH had statins omitted despite
having two or more CVD risk factors (Figure 3).
Our results prompt us to investigate other
hospitals in London to gather more evidence for
Figure 2
Pie charts showing patients prescribed statins in relation to those
with or without cardiovascular disease risk factors
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4ourhypothesisthatthereis no association between
statin prescribing habits and the socioeconomic
status of the area in which the hospitals are
based. Perhaps the failure to effectively prescribe
statins is not dependent on the socioeconomic
status of the area, but actually reﬂects a London-
wide crisis that requires immediate resolution.
In 2006, CVD cost the NHS £14 billion.
12,13 With
the huge amount of aforementioned evidence
showing that statins lower CVD events and are
an effective primary and secondary prevention
strategy, we can conclude that some of the CVD
cost burden on the NHS is the result of suboptimal
statin prescribing.
Clinical guidelines must be met in order to
provide effective prevention strategies and
beneﬁt the population in the long term. Daily
plans and events for patient care are well docu-
mented in the patients’ notes; however, it is the
drug charts which act as pivotal records from
which healthcare professionals implement drug
therapies. Drug charts already have an organized
layout so that important drug therapies are not
overlooked and also have a system of checks to
ensure due attention is placed on certain aspects
e.g. allergies. This is an ideal place for a statin pre-
scription check to take place such as a simple box
on the front page that asks the healthcare pro-
fessional to acknowledge whether or not a statin
is required, by ticking off a box. This compulsory
consideration of statin prescription should
emphasize an action to initiate a CVD risk factor
assessment of the patient.
Conclusion
This London-based audit has revealed the inade-
quacy with which patients are prescribed statins
and this will have huge implications not only for
inpatients but the continuation of this omission
when the patient is once more in the community.
Hence, there is a considerable obstacle to the
effective reduction of CVD both in the primary
and secondary prevention setting. Furthermore,
this suboptimal usage of statins in moderate to
high-risk patients is reﬂected in both London
centres, which are diverse in terms of socioeco-
nomic and geographical placement. This supports
the theory that it is actually clinician omission
rather than any other variable, i.e. localized pre-
scribing habits or patients’ economic status,
which leads to the suboptimal statin prescription.
Patients with a single CVD risk factor are the ones
who are not prescribed a statin on most occasions.
This omission is almost certainly contributing to
the CVD cost burden on the NHS and changes
in current practice could have widespread
implications, not only economically but also on
the incidence of CVevents. Furthermore, improve-
ments in secondary care drug prescribing will be
propagated into primary care, once the patient is
discharged back into their community.
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